Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 11/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 11/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | DHODH | Q02127 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9196956 | 0.99 | TDP1 (0.50) | TDP1L3MBTL1CHEK2ITGB3ITGA2B | |
| Succinic Acid SCHEMBL9213983 | 0.94 | ITGB3 (0.56) | TDP1L3MBTL1CHEK2ITGB3ITGA2B | |
| SCHEMBL9219032 | 0.94 | ITGB3 (0.54) | TDP1L3MBTL1ITGB3ITGA2BKCNH2 | |
| SCHEMBL7317389 | 0.87 | KCNH2 (0.56) | TDP1L3MBTL1KCNH2HRH3 | |
| SCHEMBL1168439 | 0.85 | TDP1 (0.50) | TDP1L3MBTL1CHEK2ITGB3ITGA2B | |
| SCHEMBL944328 | 0.83 | ITGB3 (0.57) | TDP1ITGB3ITGA2B | |
| SCHEMBL9215278 | 0.82 | ITGB3 (0.53) | ITGB3ITGA2BDHODH | |
| SCHEMBL9473478 | 0.82 | TDP1 (0.46) | TDP1L3MBTL1KCNH2HRH3 | |
| SCHEMBL9473488 | 0.82 | TDP1 (0.46) | TDP1L3MBTL1KCNH2HRH3 | |
| SCHEMBL9473475 | 0.82 | TDP1 (0.46) | TDP1L3MBTL1KCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5231184-A | Viricide intermediate | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-07-27 | — | — | US | claimed |
| US-20110003852-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HIGH POINT PHARMACEUTICALS, LLC | 2011-01-06 | — | — | US | disclosed |
| US-20110003856-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HIGH POINT PHARMACEUTICALS, LLC | 2011-01-06 | — | — | US | disclosed |
| EP-2146952-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | High Point Pharmaceuticals, LLC (US) | 2010-01-27 | — | — | EP | disclosed |
| EP-2125704-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | High Point Pharmaceuticals, LLC (US) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008101886-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HIGH POINT PHARMACEUTICALS, LLC (US) | 2008-08-28 | — | — | WO | disclosed |
| WO-2008101885-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HIGH POINT PHARMACEUTICALS, LLC (US) | 2008-08-28 | — | — | WO | disclosed |
| EP-0320032-B1 | Pyridizinamine derivatives | JANSSEN PHARMACEUTICA NV (BE) | 1995-01-18 | — | — | EP | disclosed |
| US-5231184-A | Viricide intermediate | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-07-27 | — | — | US | disclosed |
| US-5106973-A | Viricide intermediates | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-04-21 | — | — | US | disclosed |
| US-4992433-A | Viricides | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-02-12 | — | — | US | disclosed |
| EP-0320032-A1 | Pyridizinamine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1989-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003856-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HSD11B1, HSD3B1, HSD17B1 | TDP1 2110/4885L3MBTL1 3824/4885CHEK2 3911/4885 |
| US-20110003852-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HSD11B1, HSD3B1, HSD17B1 | TDP1 2110/4885L3MBTL1 3824/4885CHEK2 3911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.